Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
There may not be extensive use due to this financial obstacle and worries about injections
Kailera seeks to differentiate GLP-1/GIP agonist after partners Phase III China data Jiangsu Hengruis HRS9531 shows 17.7% placebo-adjusted weight loss at top dose Data from a Phase III study of HRS9531 in China support Jiangsu Hengruis bid for domestic approval to treat obesity, but fail to clearly differentiate the dual GLP-1/GIP agonist from established or emerging competitors
if not, conservative BUDs and single-dose formats are the safer path
The company has been involved in two lawsuits
Slide from Peter Rossings presentation- Current treatment strategies, unmet medical need, FLOW rationale, during FLOW session, 61st European Renal Association Congress The 4th pillar of DKD came as from a splash from the past
The Real Talk: Should You Do It
